LRMR News
Archived Headlines
- US IPO Pricing Recap: IPO count surpasses 2011 and 2012 totals as Markit and 9 others go public 06/23/14
- Zafgen prices upsized IPO at $16, the high end of the range 06/18/14
- 12 US IPOs planned for the week of Jun 16 06/16/14
- Obesity biotech Zafgen sets terms for $75 million IPO 06/05/14
- Obesity biotech Zafgen files for a $86 million IPO 04/18/14
Obesity biotech Gelesis does not float shares; $52 million IPO postponed
Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, postponed its IPO on Wednesday. The Boston, MA-based company was founded in 2006 and had planned to list on the NASDAQ under the symbol GLSS. Piper Jaffray,...read more
The latest weight loss capsule: Gelesis files for a $60 million IPO
Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering. The company's lead candidate uses its proprietary hydrogel technology...read more
Diabetes/Alzheimer's biotech Vitae Pharmaceuticals sets terms for $60 million IPO
Vitae Pharmaceuticals, which uses software to develop small molecule drugs for type 2 diabetes and Alzheimer's, announced terms for its IPO on Monday. The Fort Washington, PA-based company plans to raise $60 million by offering 5.0 million shares at a price...read more
Diabetes/Alzheimer's biotech Vitae Pharmaceuticals files for a $55 million IPO
Vitae Pharmaceuticals, which is using advanced software to design drugs for type 2 diabetes and Alzheimer's, filed on Tuesday with the SEC to raise up to $55 million in an initial public offering. The company claims its drug delivery platform, Countour, uses...read more